

Confirmed Speakers

Plenary Speakers

PL02 - RIPTACs: A New 'Hold and Kill'-based Therapeutic Modality



Prof. Craig CREWS
(YALE UNIVERSITY, New Haven, CT, United States)

PL03 -Carbohydrates in Health and Disease



Prof. Laura KIESSLING
(MIT, Cambridge, MA, United States)

PL01- Medicinal Chemistry of the Future: Trends, Targets and Technologies



Dr Klaus URBAHNS
(EMD SERONO, Billerica, MA, United States)

Invited Speakers

IL11 - Photocatalysis in the Pharmaceutical Industry: Synthesis under a New Light



Dr Giulia BERGONZINI
(ASTRAZENECA, Gothenburg, Sweden)

IL08 - An Intramolecular Bivalent Degradar Glues an Intrinsic BRD4-DCAF16 Interaction



Prof. Alessio CIULLI
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

IL20 - Exploiting Allostery for Computer-Aided Drug Design of Oncogenes



Dr Zoe CURNIA
(BIOMEDICAL RESEARCH FOUNDATION ACADEMY OF ATHENS, Athens, Greece)

IL10 - Frontier SBDD across the Orthosteric and Allosteric GPCRome



Dr Chris DE GRAAF
(SOSEI HEPTARES, Cambridge, United Kingdom)

IL02 - Targeting Non-Coding RNAs Using Synthetic Small Molecules: Original Targets for Innovative Therapies



Dr Maria DUCA
(UNIVERSITY OF CÔTE D'AZUR, Nice, France)

IL22 - Covalent Fragment-Based Drug Discovery

Confirmed Speakers



Dr Daniel ERLANSON
(FRONTIER MEDICINES, South San Francisco, CA, United States)

IL16 - Chemical Approaches to Enhance Cellular Immunotherapies



Dr Mark P. FARRELL
(UNIVERSITY OF KANSAS, Lawrence, KS, United States)

IL01 - Modulating the Conformation and Function of Disease-Relevant RNA with Small Molecules



Prof. Amanda HARGROVE
(DUKE UNIVERSITY, Durham, NC, United States)

IL04 - Small Molecules Targeting RNA - a Safety Perspective



Dr Helen Louise LIGHTFOOT
(F. HOFFMANN-LA ROCHE AG, BASEL, Switzerland)

IL12 - HTE Chemistry to Accelerate Medicinal Chemistry Programs



Dr Fabio LIMA
(NOVARTIS, Basel, Switzerland)

IL05 - Ligand Directed Degradation: from Proof-of-Concept Degradation to Clinical Studies



Dr Deborah MORTENSEN
(BRISTOL MYERS SQUIBB, San Diego, CA, United States)

IL09 - New Hot Targets? Medicinal Chemistry of G Protein-Coupled Receptors Involved in Immunity and Cancer



Prof. Christa MÜLLER
(UNIVERSITY OF BONN, Bonn, Germany)

IL07 -Chemoproteomic-Enabled Development of Proximity-Inducing Molecules



Dr Christopher PARKER
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA, United States)

IL15 - E3 Ligase Ligand Discovery for TPD



Dr Benika PINCH
(NOVARTIS, Cambridge, MA, United States)

IL21 - RAPID – a Next-Generation Chemoproteomics Technology Enabling the Discovery of Reversible Binders to Pre-specified Targets in Living Cells

ACSMEDI-EFMC Medicinal Chemistry Frontiers 2023

Confirmed Speakers



Dr Justin RETTENMAIER
(JNANA THERAPEUTICS, Boston, MA, United States)

IL17 - Machine Learning Tools to Accelerate Chemical Biology Studies



Dr Tiago RODRIGUES
(UNIVERSITY OF LISBON, Lisbon, Portugal)

IL18 - A Computation-First Approach to Drug Challenging Disease Targets



Dr Woody SHERMAN
(PSIVANT THERAPEUTICS, Boston, MA, United States)

IL13 - Chemical Probes Enabling Drug Target Discovery and Validation



Prof. Edward TATE
(IMPERIAL COLLEGE LONDON, London, United Kingdom)

IL23 - Large-scale in Silico Fragment Screening of ~200 Million Fragments Based on Absolute Free Energy Perturbation



Dr Eric THERRIEN
(SCHRODINGER, New York, NY, United States)

IL03 - Discovery and Development of Selective Splicing Modifiers as Therapeutics



Dr Matthew WOLL
(PTC THERAPEUTICS, South Plainfield, NJ, United States)

IL06 - Chemical Approaches to Edit Post-Translational Modification In Cells



Prof. Christina WOO
(HARVARD UNIVERSITY, Cambridge, MA, United States)

IL19 - X-ray Crystallographic Fragment Screening for the Identification of Allosteric Binding Sites



Dr Andrew WOODHEAD
(ASTEX THERAPEUTICS, Cambridge, United Kingdom)

IL14 - Generating Stem-Like T Cells with Small-Molecule Modulators for Cancer Immunotherapy



Prof. Peng WU
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA, United States)

Oral Communications

Confirmed Speakers

OC11 - Chemical Probes for RHO GEF/GTPase Complexes



Ms Mia CALLENS
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

OC01 - Treatment of Pediatric AML Via Protac-Mediated Degradation of CDK9



Ms Alexandria CHAN
(UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY, Baltimore, United States)

OC12 - Potent Targeted Activator of Cell Kill Molecules Selectively Eliminate HIV Infected Cells



Dr Abdellatif EL MARROUNI
(MERCK & CO., West Point, United States)

OC03 - Discovery of MRT-2359, an Orally Bioavailable GSPT1 Molecular Glue Degradator, for MYC-Driven Cancers



Dr Bernhard FASCHING
(MONTE ROSA THERAPEUTICS, Basel, Switzerland)

OC10 - Azetidin-2-Ones as Quenched Activity-Based Probes to Profile Human Neutrophil Elastase in Proteomes



Ms Rita FÉLIX
(IMED.U LISBOA - RESEARCH INSTITUTE FOR MEDICINES, Lisbon, Portugal)

OC07 - New Precision Anti-TB Agents by Allosteric Inhibition of Glutamate-5-Kinase Enzyme



Prof. Concepcion GONZALEZ-BELLO
(UNIVERSIDADE DE SANTIAGO DE COMPOSTELA - CIQUS, Santiago de Compostela, Spain)

OC15 - Small Molecule Drug Discovery with Peptide-Encoded Libraries



Dr Nathalie GROB
(MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, United States)

OC04 - Integrated Platform Approach for Molecular Degradator Discovery in Prodrugs



Dr Johanna HUCHTING
(FRAUNHOFER INSTITUTE FOR TRANSLATIONAL MEDICINE AND PHARMACOLOGY, Hamburg, Germany)

OC14 - Structure-Based Drug Discovery and Umbrella Sampling Simulations Identify Novel Potent Troponin Calcium Sensitizers and Elucidate their Function

Confirmed Speakers



Prof. Steffen LINDERT
(OSU, Columbus, United States)

OC06 - Targeting Sodium Binding Pocket in Mu Opioid Receptor to Design Safer Analgesics



Dr Susruta MAJUMDAR
(UHSP & WASHINGTON UNIVERSITY, Saint Louis, United States)

OC05 - Best-In-Class Orally Bioavailable CXCR4 Antagonists to Treat Renal Cell Carcinoma



Dr Eric MILLER
(EMORY UNIVERSITY SCHOOL OF MEDICINE, Atlanta, United States)

OC02 - Targeting Progerin Degradation as a New Therapeutic Approach for Treating Progeria



Prof. Silvia ORTEGA-GUTIERREZ
(COMPLUTENSE UNIVERSITY, Madrid, Spain)

OC08 - Impact of gem-Difluoromethylene Group on Physicochemical Properties in Medchem-Relevant Building Blocks



Dr Sergey RYABUKHIN
(ENAMINE LTD, Kyiv, Ukraine)

OC13 - Borrowing Transcriptional Kinases to Activate Apoptosis Using Chemically Induced Proximity



Dr Roman SAROTT
(STANFORD UNIVERSITY, Menlo Park, United States)

OC09 - Targeting Receptor Complexes with Therapeutic Peptides



Prof. Kristian STROMGAARD
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)